To investigate predictors of response, remission, low disease activity (LDA), damage and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with belimumab.
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus
Gatto, Mariele;Negrini, Simone;
2020-01-01
Abstract
To investigate predictors of response, remission, low disease activity (LDA), damage and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with belimumab.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Arthritis Rheumatology - 2020 - Gatto - Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in (1).pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
408.74 kB
Formato
Adobe PDF
|
408.74 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
